The aim of this article is to describe the 2017 revised consensus criteria for the clinical diagnosis of dementia with Lewy bodies (DLB) with future directions for the diagnostic criteria. The criteria for the clinical diagnosis of probable and possible DLB were first published as the first consensus report in 1996 and were revised in the third consensus report in 2005. After discussion at the International DLB Conference in Fort Lauderdale, Florida, USA, in 2015, the International DLB Consortium published the fourth consensus report including the revised consensus criteria in 2017. The 2017 revised criteria clearly distinguish between clinical features and diagnostic biomarkers. Significant new information about previously reported aspects of DLB has been incorporated, with increased diagnostic weighting given to rapid eye movement (REM) sleep behavior disorder (RBD) and iodine-123-metaiodobenzylguanidine (MIBG) myocardial scintigraphy. Future directions include the development of the criteria for early diagnosis (prodromal DLB) and the establishment of new biomarkers that directly indicate Lewy-related pathology, including α-synuclein imaging, biopsies of peripheral tissues (skin, etc.) for the demonstration of α-synuclein deposition, and biochemical markers (cerebrospinal fluid/blood), as well as the pathological evaluation of the sensitivity and specificity of the 2017 revised diagnostic criteria. In conclusion, the revised consensus criteria for the clinical diagnosis of DLB were reported with the incorporation of new information about DLB in 2017. Future directions include the development of the criteria for early diagnosis and the establishment of biomarkers directly indicative of Lewy-related pathology. cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/ licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Neurodegenerative diseases characterized by the accumulation of aggregated α-synuclein have been referred to as α-synucleinopathies. Among α-synucleinopathies, Lewy body diseases are characterized by the accumulation of aggregated α-synuclein into Lewy bodies and Lewy neurites in neurons and neuronal processes (Lewy-related pathology). 1 Lewy body diseases include Parkinson' s disease (PD), PD with dementia (PDD), dementia with Lewy bodies (DLB), and other disorders. Among neurodegenerative diseases causing dementia, DLB is second to Alzheimer' s disease (AD).
In Lewy body diseases, Lewy-related pathology is distributed in the central and peripheral nervous systems frequently accompanying AD-type neuropathology, which results in the dysfunction and death of synapses and neurons in various areas of the nervous system. Furthermore, patterns of the extension and speed of Lewy-related pathologies are not uniform, including ascending, descending, and olfactory routes that have been considered to be related to the intraneuronal and transsynaptic propagation JMD of α-synuclein aggregates in the nervous system with a prion-like mechanism. [2] [3] [4] The complexity of the pathophysiology of Lewy body diseases is linked to considerable variations in clinical manifestations and courses, showing multiple phenotypes, such as PD, PDD, and DLB. DLB is a clinically defined term for dementia with other clinical manifestations characteristic of Lewy-related pathologies, which have been based on a retrospective review of the clinical histories of pathologically confirmed cases.
Pathological studies with autopsy samples from the general population showed that Lewy body pathology, found in 22.5% of the general population and 41.4% of the demented subjects, often coexists with AD pathology, and aging and AD have strong effects on the evolution of DLB pathology, influencing clinical severity and prognosis. 5 The true prevalence of DLB and the mixed disease of AD with DLB is likely to be much higher than that of clinically recognized cases; DLB diagnoses are often missed. 6 These findings indicate the limitation of current diagnostic criteria and biomarkers to sensitively detect patients with DLB or the mixed dementia of DLB and AD.
It is required that the criteria for the clinical diagnosis of DLB can detect various clinical phenotypes and laboratory findings of DLB with enough sensitivity and exclude AD and other diseases with high specificity. This article describes a historical review of the criteria for the clinical diagnosis of DLB by the International DLB Consortium, efforts by the authors to upgrade the diagnostic value of 123 I-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy, the 2017 revised diagnostic criteria, and future directions to further improve the diagnostic criteria for DLB.
BRIEF HISTORICAL REVIEW OF THE DIAGNOSTIC CRITERIA FOR DLB: THE 1996 ORIGINAL CRITERIA AND 2005 REVISED CRITERIA
After the first international workshop on DLB held in New-castle upon Tyne in 1995, the first consensus guidelines were published in 1996, including the consensus criteria for the clinical diagnosis of probable and possible DLB. 7 The 1996 criteria were simple ( Table 1 ). The progressive cognitive decline of sufficient magnitude to interfere with normal social or occupational function was the central feature, always required. There were three core features: fluctuating cognition, visual hallucinations, and parkinsonism; two of the three core features were essential for probable DLB, and one was essential for possible DLB. In addition, supportive features and less likely cases of DLB diagnosis were described as shown in Table 1 . After the second international workshop on DLB held in Amsterdam in 1998, the second consensus report was published in 1999; 8 there was no revision of the diagnostic criteria.
The third DLB/PDD International Workshop was held in Newcastle upon Tyne in 2003. After this meeting, the third report of the DLB consortium was published in 2005, including the revised criteria for the clinical diagnosis of DLB. 9 In the 2005 revised criteria (Table 2) , the central feature and three core features were the same as in the 1996 original criteria. In this revision, "suggestive features" were added, including 1) rapid eye movement (REM) sleep behavior disorder (RBD), 2) severe neuroleptic sensitivity, and 3) low dopamine transporter (DAT) uptake in basal ganglia demonstrated by single photon emission computed tomography (SPECT) or positron emission tomography (PET) imaging, such as 123 iodine-labeled N-(3-fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl) nortropane ( 123 I-FP-CIT) SPECT. If one or more suggestive features were present in the presence of one core feature, a diagnosis of probable DLB could be made. It should be noted that, in addition to clinical features, biomarkers were included in this revised criteria as suggestive and supportive features.
In 2006, the fourth International Workshop on DLB and PDD was held in Yokohama. As it was just after the publication of the 2005 revised criteria, there was no revision of the criteria. In December 2015, the International DLB Conference was held in Fort Lauderdale, Florida. Based on the discussion at the Florida conference incorporated with new information on DLB, the fourth consensus report of the DLB Consortium in 2017 was published, including the new diagnostic criteria. 10
STUDIES FOR UPGRADING 123 I-MIBG MYOCARDIAL SCINTIGRAPHY IN THE DIAGNOSTIC CRITERIA FOR DLB
The usefulness of 123 I-MIBG myocardial scintigraphy for the clinical diagnosis of DLB has been reported since 2001 by our group and other groups as single-center studies. 11-14 123 I-MIBG is an analog of norepinephrine and accumulates in sympathetic nerve terminals soon after intravenous administration. The MIBG uptake reflects the density, distribution, and activity of postganglionic sympathetic nerves that are involved in Lewy body diseases, including PD and DLB. As a measure of cardiac MIBG uptake, the heart to mediastinum (H/M) ratio is calculated in early (20 minutes) and delayed (3 hours) images after the intravenous injection of 123 I-MIBG ( Figure 1A ). As patients with DLB, but not AD, frequently present with postganglionic sympathetic nerve lesions caused by Lewy-related pathology, the myocardial uptake of MIBG is clearly and diffusely reduced in DLB compared with AD in early and delayed images, showing a significant difference in the H/M ratio between AD and DLB ( Figure 1B) . A meta-analysis of single-center studies showed very high sensitivity, 98%, and very high specificity, 94%. 15 However, it should be noted that, except for Lewy body diseases, cardiac diseases (heart failure, ischemic heart disease, etc.), metabolic or endocrine diseases (diabetes mellitus, pheochromocytoma, etc.), neurological diseases with postganglionic sympathetic nerve lesions (peripheral neuropathies such as diabetic neuropathy and amyloid neuropathy), and the use of some medicines (sympathomimetics, tricyclic antidepressants, labetalol, reserpine, etc.) are associated with a reduction in the cardiac uptake of MIBG and may give false-positive MIBG results. 14 In the 2005 revised criteria, MIBG myocardial scintigraphy was classified as one of the supportive features and not as a suggestive feature such as DAT imaging. To increase the diagnostic weighting of MIBG in the criteria, 1) the standardization of the MIBG techniques, 2) a multicenter study with standardized MIBG, and 3) the direct comparison of MIBG data with pathological findings were required.
First, we standardized data acquisition and processing methods for 123 I-MIBG imaging. Differences among collimators in institutions were standardized by using a calibration phantom. 16, 17 The setting of regions of interests (ROIs) for the heart and medi- 
A diagnosis of DLB is less likely:
a. In the presence of cerebrovascular disease evident as focal neurological signs or on brain imaging b. In the presence of any other physical illness or brain disorder sufficient to account in part or in total for the clinical picture c. If parkinsonism only appears for the first time at a stage of severe dementia 6. Temporal sequence of symptoms: JMD astinum was semiautomated using "smartMIBG" (standardized method for automatic ROI setting in MIBG study). 18 These methods made it possible to obtain standardized data of the H/M ratio from different institutions. At present, the calibration phantom method has further been extended to European countries to overcome differences in H/M ratios depending on camera-collimator combinations. 19 Next, we performed a prospective multicenter study to evaluate cardiac sympathetic function for the diagnosis of DLB, involving 10 institutions in Japan. Independent committees performed clinical and MIBG assessments. A total of 133 patients were registered, including probable DLB, possible DLB, and probable AD cases. The DLB diagnoses were based on the 2005 revised criteria. 9 The first baseline study was based on the baseline MIBG data and baseline diagnoses. 20 The second three-year follow-up study was based on baseline MIBG data and the final clinical diagnosis 3 years after. 21 ROC curves for the detection of probable DLB from probable AD with early and delayed H/M ratios at baseline MIBG on the basis of baseline and 3-year follow-up diagnoses are shown in Figure 2 . The three-year followup improved the ROC curve, giving a sensitivity of 77% and a specificity of 97%. Among patients with the diagnosis of possible DLB at baseline (n = 10), the diagnosis was changed to probable DLB (n = 6), probable AD (n = 1), and other disease (depression) (n = 1), while the other two remained as possible DLB during the 3-year follow-up. Five of six patients who were diagnosed with possible DLB at baseline and with probable DLB at follow-up had a reduced H/M ratio at baseline. Two patients who were diagnosed with possible DLB at baseline and with other diagnoses (AD or depression) at follow-up showed no significant reduction in H/M ratio at baseline. Two patients who were diagnosed with possible DLB at baseline and remained with possible DLB at follow-up showed a reduced H/M ratio at baseline. Thus, a reduction in MIBG uptake may be useful for diagnosis in the early stage of DLB. 21 Pathologically, Lewy body diseases are associated with the deposition of phosphorylated α-synuclein in cardiac sympathetic nerves and sympathetic ganglia and a marked loss of tyrosine hydroxylase (TH)-positive sympathetic nerve fibers in the heart walls. 22 It was revealed that cardiac MIBG uptake for early and delayed images was correlated with the proportion of residual cardiac sympathetic TH-positive nerve fibers at autopsy. 23 Thus, it was established that a reduction in cardiac MIBG uptake is a marker of postganglionic sympathetic nerve lesions caused by Lewy-related pathology. Based on the high diagnostic specificity in our multicenter study with standardized techniques and pathological evidence, the weighting of MIBG was upgraded in the revised 2017 criteria for the clinical diagnosis of DLB.
THE 2017 REVISED CRITERIA FOR THE CLINICAL DIAGNOSIS OF DLB
The points of revision in the 2017 criteria 10 are as follows: 1) the 2017 criteria distinguish clearly between clinical features and diagnostic biomarkers, and 2) significant new information about previously reported aspects of DLB has been incorporated into the 2017 revised criteria, with increased diagnostic weighting given to RBD and MIBG.
The 2017 criteria are shown in Table 3 . 10 The central feature is dementia. The other features are divided into clinical features and For dementia as the central feature, prominent memory impairment may not occur in the early stages of DLB, but deficits of attention, executive function, and visuoperceptual ability may be prominent.
As a core clinical feature, RBD is added to the three core features (fluctuating cognition, visual hallucinations, and parkinsonism) of the previous 2005 criteria. Fluctuation is typically delirium-like, occurring as spontaneous alterations in cognition, attention, and arousal. It is recommended to document at least one measure of fluctuation when applying DLB diagnostic criteria. [24] [25] [26] [27] Visual hallucinations are typically well formed, featuring people, children or animals, sometimes accompanied by related phenomena such as passage hallucinations, a sense of presence, and visual illusions. For parkinsonism, parkinsonism in DLB frequently falls short of that in PD characterized by combinations of bradykinesia, resting tremor, and rigidity; one or more spontaneous features of parkinsonism are required in the DLB diagnostic criteria. RBD is characterized by recurrent dream enactment behavior that includes movements mimicking dream content and is associated with an absence of normal REM sleep atonia.
The inclusion of RBD as a core clinical feature has been reported to improve the diagnostic accuracy of DLB based on a study with autopsy-confirmed DLB and non-DLB cases, 28 which was sufficient to justify upgrading RBD from a suggestive feature (2005) 9 to a core clinical feature (2017). 10 RBD may begin many years before and may become quiescent over time. RBD should be screened using a scale that allows for patient or bed partner report. 29, 30 Supportive clinical features may indicate the diagnosis of DLB, although they lack diagnostic specificity. They include severe antipsychotic sensitivity; postural instability; repeated falls; hypersomnia, usually presenting as excessive daytime sleepiness; syncope; transient episodes of unresponsiveness, which may be an extreme form of cognitive fluctuation and difficult to distinguish from true syncope; severe autonomic dysfunction (orthostatic hypotension/constipation/urinary incontinence); hyposmia, which occurs earlier in DLB that in AD; hallucinations in other modalities; systematized delusions; apathy; anxiety; and depression. "Severe sensitivity to antipsychotic agents" was changed from one of the suggestive features in the 2005 criteria 9 to one of the supportive clinical features in the 2017 criteria 10 because a significant reduction in prescribing D2 receptor blocking antipsychotics in DLB limits its diagnostic usefulness, although cau- tion about their use remains unchanged. 10 Indicative biomarkers are 1) reduced DAT uptake in basal ganglia on PET or SPECT, such as FP-CIT; 2) low MIBG uptake; and 3) the polysomnographic confirmation of RBD, i.e., REM sleep without atonia (RWA). High specificities of reduced uptake in DAT imaging, low MIBG uptake in MIBG myocardial scintigraphy, and RWA on polysomnography (PSG) for DLB diagnosis have been well established. 20, 21, 31, 32 Studies with a direct comparison of 123 I-FP-CIT SPECT and 123 I-MIBG scintigraphy in the differential diagnosis of DLB and AD or other dementias 
DLB and PDD
DLB should be diagnosed when dementia occurs before or concurrently with parkinsonism. The term PDD should be used to describe dementia that occurs in the context of well-established Parkinson's disease. In a practice setting, the term that is most appropriate to the clinical situation should be used, and generic terms such as Lewy body disease are often helpful. In research studies in which distinction needs to be made between DLB and PDD, the existing 1-year rule between the onset of dementia and parkinsonism continues to be recommended. showed similar diagnostic sensitivity (90% for both methods) and specificity (91% for both methods), 33 35 123 I-MIBG scintigraphy may be more specific than 123 I-FP-CIT SPECT, especially when parkinsonism is the only "core feature exhibited by the patient. " 35 For PSG, RWA on PSG in a person with dementia and a history of RBD is associated with a ≥ 90% likelihood of pathologically proven synucleinopathy, 32 indicating a high diagnostic specificity of PSG-confirmed RBD even in the absence of any other core feature or indicative biomarker. In earlier stages, PSG-confirmed idiopathic RBD and even incidental RWA on PSG without RBD may be associated with an early transition to DLB or PD, especially when combined with abnormalities in 123 I-FP-CIT SPECT or 123 I-MIBG scintigraphy; [36] [37] [38] [39] abnormalities in 123 I-FP-CIT SPECT, 123 I-MIBG scintigraphy, and PSG would be useful to identify prodromal DLB/PD.
For the diagnosis of probable DLB, "two or more core clinical features" or "one core clinical feature, but with one or more indicate biomarkers" is required. For the diagnosis of possible DLB, "one core clinical feature" or "one or more indicative biomarkers, but no core clinical features" is necessary. The diagnosis of probable DLB is not allowed on the basis of only biomarkers.
Regarding the terms DLB and PDD, in a practice setting, DLB is used when dementia occurs before or concurrently with parkinsonism, and PDD is used when dementia occurs in the context of well-established PD. In a research setting, to distinguish DLB from PDD, the 1-year rule between the onset of dementia and parkinsonism is recommended; DLB is used when dementia occurs before or within one year after the onset of parkinsonism; the 1-year rule is operational with no scientific basis; and DLB and PDD have been considered to represent phenotypic differences in a spectrum of Lewy body diseases.
To improve the diagnosis of Lewy body dementias (DLB or PDD), assessment toolkits were developed to be easy to use by clinicians and to align with the consensus diagnostic criteria for DLB 40 and were updated for the 2017 revised criteria. 41 
FUTURE DIRECTIONS TO IMPROVE THE DIAGNOSTIC CRITERIA FOR DLB
To further improve the 2017 revised diagnostic criteria for DLB, future directions include 1) the evaluation of the sensitivity and specificity of the 2017 revised criteria by pathologically confirmed cases; 2) the development of the criteria for prodromal DLB, and, further, preclinical DLB to detect early-stage disease; and 3) the establishment of new biomarkers as well as further characterization of clinical features specific to DLB.
Concerning the pathological evaluation of the criteria for clinical diagnosis, mixed pathologies, especially the frequent co-occurrence of AD-related pathology, complicate the pathophysiological and clinical manifestations of DLB. 42, 43 In the diagnostic criteria, the likelihood that the pathological findings are associated with a typical DLB clinical syndrome is assessed on the basis of the staging of Lewy-related pathology and AD pathology. 10 It is recommended to measure reliable biomarkers for AD pathology for the precise clinical diagnosis of DLB. In addition, the distribution of the Lewy-related pathology responsible for each cognitive/psychiatric symptom should be further elucidated with careful clinicopathological studies. 44 The diagnostic criteria for prodromal DLB are under development. [45] [46] [47] [48] The diversity in the clinical course of DLB is related to the difficulty in developing the diagnostic criteria for prodromal DLB. Clinical manifestations at the prodromal stage include mild cognitive impairment (MCI) (particularly, non-amnestic MCI characterized by attentional, executive, and visuo-constructive dysfunctions), RBD, behavioral and psychiatric symptoms (hallucinations, depression, etc.), delirium, mild parkinsonian signs, autonomic dysfunction (constipation, orthostatic hypotension, etc.), and hyposmia. It was reported for MCI with Lewy bodies (MCI-LB) that the presence of supportive neuropsychiatric clinical features identified in the 2017 DLB diagnostic criteria was helpful in differentiating MCI-LB from MCI-AD. 49, 50 Neuroimaging and biochemical markers that are currently available 48, 51 or under development (as described below) would offer great potential for early diagnosis at the prodromal and, further, preclinical stages of DLB and require further studies. Prospective longitudinal studies with pathological verification are essential to establish the diagnostic criteria for prodromal DLB. Methods to develop consensus criteria for prodromal DLB were discussed in the International Lewy Body Dementia Conference held in Las Vegas, Nevada, in June 2019.
No disease-modifying therapies (DMTs) are available for α-synucleinopathies as yet, although the development of DMTs targeting α-synuclein is ongoing with several approaches, including decreasing α-synuclein production with RNA interference, inhibiting α-synuclein aggregation, promoting the intracellular degradation of α-synuclein aggregates via enhancing autophagy or enhancing lysosomal degradation, and promoting the extracellular degradation of α-synuclein via active and passive immunization. 52 At the same time, biomarkers that directly indicate the presence of Lewy-related pathology need to be established. These biomarkers include α-synuclein imaging; the detection of α-synuclein deposition by biopsies of skin and other tissue; cerebrospinal fluid (CSF) and blood biochemical markers such as α-synuclein, phosphorylated α-synuclein, misfolded α-synuclein, and α-synuclein aggregates; and genetic markers such as the α-synuclein gene (SNCA). Concerning the molecular imaging of DLB, there are limitations of current imaging biomarkers, requiring tracers with high affinity for α-synuclein. 53 The abnormal deposition of α-synuclein can be pathologically revealed in peripheral tissues (Figure 3 ). For the pathological demonstration of abnormal α-synuclein using biopsies, phosphorylated α-synuclein deposits in skin nerve fibers on skin biopsy have been reported to be a sensitive biomarker for DLB diagnosis. It was reported that phosphorylated α-synuclein deposits were detected in the skin nerve fibers of all patients with DLB, but no deposits were detected in healthy controls or in patients with nonsynucleinopathy dementia. 54 Among the synucleinopathies, DLB showed the highest phosphorylated α-synuclein load with a widespread involvement of autonomic skin fibers compared with PD or multiple system atrophy. 55 Furthermore, phosphorylated α-synuclein deposits could be detected with skin biopsies in 75% of idiopathic RBD patients, suggesting the possibility of usefulness even in the prodromal stage of DLB, such as idiopathic (isolated) RBD. 56 We need a standardization of the techniques used for α-synuclein immunohistochemistry and multicenter studies to establish the diagnostic value of biopsies of skin or other peripheral tissues.
For the biochemical detection of α-synuclein in biofluids, decreased CSF levels of total α-synuclein and increased CSF levels of oligomeric α-synuclein in DLB have been reported, however, there are tremendous overlaps between levels in DLB patients and in controls; the combination of α-synuclein species and AD biomarkers (Aβ1-42/tau) improves the diagnostic performance to differentiate DLB from AD. [57] [58] [59] For plasma α-synuclein as a blood biomarker, analytical limitations still remain. Assays for the sensitive detection of pathological species of α-synuclein, misfolded or aggregated α-synuclein are under development. It was reported that real-time quaking-induced conversion (RT-QuIC) and protein misfolding cyclic amplification (PMCA) methods allow the amplification of α-synuclein misfolded aggregates in CSF with high sensitivity and specificity. [60] [61] [62] It was shown with a PMCA assay of CSF that the sensitivity for the detection of DLB was 100% and that the specificity was more than 90%. 62 We need confirmation of the usefulness of these CSF assays by multicenter studies with standardized RT-QuIC/PMCA methods. Furthermore, CSF exosomes from patients with PD and DLB were reported to contain a pathogenic species of α-synuclein, which could initiate the oligomerization of soluble α-synuclein in target cells, suggesting the possibility of a pathogenic biomarker. 63 In addition, a recent study with gastrointestinal biopsies reported good agreement between α-synuclein immunohistochemistry and a PMCA of α-synuclein aggregates using biopsy samples. 64 
CONCLUSIONS
The revised consensus criteria for the clinical diagnosis of DLB were published in 2017 with the incorporation of new information about DLB. For earlier and more likely diagnoses of DLB, it is required to elucidate phenotypic variations in Lewy body diseases, including DLB, and to establish reliable diagnostic biomarkers that directly indicate the presence of abnormal α-synuclein accumulations related to Lewy-related pathology.
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